Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Healthcare (Basel, Switzerland)|January 17, 2019
Acute Kidney Injury Pharmacokinetic Changes and Its Impact on Drug PrescriptionVictoria E Blanco, Carolina V Hernandorena, Paula Scibona, et al.
Medicina|June 22, 2026
Antibiotic resistance: and now what?Francisco Nacinovich, Waldo Belloso, Yanina Nuccetelli, et al.
AIDS (London, England)|August 8, 2013
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapyAllison Martin, Cecilia Moore, Patrick W G Mallon, et al.
Plos Medicine|October 24, 2008
Inflammatory and coagulation biomarkers and mortality in patients with HIV infectionLewis H Kuller, Russell Tracy, Waldo Belloso, et al.
The Lancet. Infectious Diseases|April 17, 2015
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Dianne Carey, Rebekah Puls, et al.
International Journal of Antimicrobial Agents|July 3, 2017
Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trialAmit C Achhra, Amanda Mocroft, Michael Ross, et al.
Plos One|September 13, 2012
Inflammation, coagulation and cardiovascular disease in HIV-infected individualsDaniel A Duprez, Jacqueline Neuhaus, Lewis H Kuller, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySarah Lilian Pett, Janaki Amin, Andrejz Horban, et al.
JAMA Network Open|January 25, 2022
Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent PlasmaHyung Park, Thaddeus Tarpey, Mengling Liu, et al.
Pageof 1